Last reviewed · How we verify
Benzokain Sprey
Benzokain Sprey is a Local anesthetic Small molecule drug developed by TC Erciyes University. It is currently in Phase 3 development for Topical anesthesia for minor pain and discomfort (spray formulation).
Benzocaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission.
Benzocaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission. Used for Topical anesthesia for minor pain and discomfort (spray formulation).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Benzokain Sprey |
|---|---|
| Sponsor | TC Erciyes University |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management / Anesthesia |
| Phase | Phase 3 |
Mechanism of action
Benzocaine works by inhibiting sodium influx through voltage-gated sodium channels in sensory nerve fibers, thereby preventing depolarization and blocking the generation and conduction of action potentials. This results in local anesthesia of the area where the spray is applied. As a topical spray formulation, it provides rapid onset of anesthesia at the site of application.
Approved indications
- Topical anesthesia for minor pain and discomfort (spray formulation)
Common side effects
- Localized irritation or burning at application site
- Allergic contact dermatitis
- Methemoglobinemia (rare, with excessive use)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benzokain Sprey CI brief — competitive landscape report
- Benzokain Sprey updates RSS · CI watch RSS
- TC Erciyes University portfolio CI
Frequently asked questions about Benzokain Sprey
What is Benzokain Sprey?
How does Benzokain Sprey work?
What is Benzokain Sprey used for?
Who makes Benzokain Sprey?
What drug class is Benzokain Sprey in?
What development phase is Benzokain Sprey in?
What are the side effects of Benzokain Sprey?
What does Benzokain Sprey target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: TC Erciyes University — full pipeline
- Therapeutic area: All drugs in Pain management / Anesthesia
- Indication: Drugs for Topical anesthesia for minor pain and discomfort (spray formulation)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing